Sort by
Refine Your Search
-
Listed
-
Category
-
Employer
-
Field
-
agreed. The Postdoctoral/Doctoral Researcher will be offered a full-time contract for 2-3 (Postdoctoral) or 3 (Doctoral) years, with the possibility of extension after the end of the contract. There will
-
software (e.g. R, Stata). Ability to work both independently and as part of a research team. Good command of the English language. The eligibility requirements for the position must be fulfulled by the end
-
by the Department of Computing. The position is full-time and fixed term, starting on November 1, 2025 (or later upon mutual agreement) and ending on August 31, 2029. Job description The successful
-
of extension after the end of the contract. There will be a trial period of six months at the beginning of employment. Position description The successful candidate will work within the research project
-
Software Engineer] to a postdoctoral-level position. The desired start dates would be as soon as possible in 2025. Are you more of a programmer than your researcher colleagues? Are you more of a researcher than
-
Fellow, you will develop a collaborative project under the supervision of two Nordic EMBL PIs at two different sites. You will obtain a 30-month, full time postdoctoral employment at the institution
-
biology and conservation. This project combines experimental evolution, single-cell sequencing (scRNA-seq, scATAC-seq), and whole-genome resequencing to resolve the genetic, regulatory, and transcriptional
-
letters with the contact details of two referees. MORE INFORMATION Frans Mäyrä, frans.mayra@tuni.fi Olli Sotamaa, olli.sotamaa@tuni.fi Application period starts: 2025-09-30 15:00. Application period ends
-
close collaboration and innovation. Together, they drive ecosystem development by combining cutting-edge research with industrial expertise, fostering new technologies, business models, and talent
-
aims to train experts and leaders in the broad field of immunology who will advance research to address the needs in the prevention and treatment of immune-mediated diseases. Its goals are breakthrough